CureVac

CureVac is one of the original pioneers of mRNA technology, having worked on messenger RNA therapeutics since 2000, well before the technology gained global prominence during the COVID-19 pandemic. The company's proprietary mRNA platform is designed to optimize unmodified mRNA for prophylactic vaccines, oncology, and rare diseases, offering a distinct scientific approach from competitors like BioNTech and Moderna. CureVac's continued development represents a critical pillar of European biotechnology sovereignty, ensuring the continent retains independent capacity in one of the most transformative medical technologies of the century.